Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-471-4 | CAS number: 60-34-4
Neurotoxicity
Administrative data
- Endpoint:
- neurotoxicity
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Non-GLP, no guideline applicable (mechanistic data). Possibly usefull for antidote therapy.
Data source
Referenceopen allclose all
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 964
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 965
- Report date:
- 1965
Materials and methods
- Principles of method if other than guideline:
- Not applicable: mechanistic study.
- GLP compliance:
- no
- Remarks:
- prior to GLP
Test material
- Reference substance name:
- Methylhydrazine
- EC Number:
- 200-471-4
- EC Name:
- Methylhydrazine
- Cas Number:
- 60-34-4
- Molecular formula:
- CH6N2
- IUPAC Name:
- methylhydrazine
- Details on test material:
- data on other hydrazine compounds are ignored here
Constituent 1
Results and discussion
Applicant's summary and conclusion
- Conclusions:
- Based on results in mice, pyridoxine, amino-oxyacetic acid or p-dimethylaminobenzaldehyde are possible antidote candidates in case of acute toxicity of MMH. Their relevance and safety should be assessed by a physician.
- Executive summary:
Taken from the abstract and limited to MMH (other investigated substances were of the hydrazine family):
The mechanism and site of toxic activity of MMH (methylhydrazine) were investigated by acute toxicity studies in mice, by studying cardiovascular and autonomic effects in dogs, by noting the effect on convulsions of transection of the central nervous system at several levels in dogs, and by evaluating selected protective agents in mice. Four separate mechanisms of action are suggested by differences in pharmacologic activity. MMH manifests its MAO inhibitory activity by intensifying the response to tyramine. MMH convulsions originate in a pre-pontine area. In mice, prevention from the effects of MMH, is achieved by pyridoxine and amino-oxyacetic acid. p-dimethylaminobenzaldehyde, but not p-chlorobenzaldehyde or p-nitrobenzaldehyde, protects against the effects of MMH in mice. However, none of the tested items worked to avoid convulsions and death in rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
